Fortress Biotech (NASDAQ:FBIO – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Fortress Biotech to related companies based on the strength of its dividends, institutional ownership, profitability, earnings, risk, valuation and analyst recommendations.
Volatility & Risk
Fortress Biotech has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Fortress Biotech’s competitors have a beta of -0.05, indicating that their average stock price is 105% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Fortress Biotech and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fortress Biotech | 1 | 1 | 2 | 0 | 2.25 |
| Fortress Biotech Competitors | 7819 | 13779 | 25784 | 1035 | 2.41 |
Fortress Biotech currently has a consensus price target of $17.00, indicating a potential upside of 745.77%. As a group, “Pharmaceuticals” companies have a potential upside of 23.79%. Given Fortress Biotech’s higher possible upside, analysts plainly believe Fortress Biotech is more favorable than its competitors.
Valuation & Earnings
This table compares Fortress Biotech and its competitors gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Fortress Biotech | $63.26 million | $6.82 million | 0.76 |
| Fortress Biotech Competitors | $5.37 billion | $3.23 billion | 555.01 |
Fortress Biotech’s competitors have higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Fortress Biotech and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fortress Biotech | 163.32% | 83.47% | 42.98% |
| Fortress Biotech Competitors | -2,393.16% | -220.83% | -16.11% |
Summary
Fortress Biotech beats its competitors on 7 of the 13 factors compared.
Fortress Biotech Company Profile
Fortress Biotech, Inc. (NASDAQ: FBIO) is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiary companies and strategic partnerships. Its research and development activities have focused on areas including dermatology, immunology, oncology, rare diseases and other conditions with significant unmet medical needs. The company’s portfolio has included dermatology products such as ZILXI, a topical minocycline foam for the treatment of inflammatory lesions associated with rosacea, and Qbrexza, a topical treatment for primary axillary hyperhidrosis.
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
